SCHEMBL5259185

SCHEMBL5259185

COc1ccc2ccccc2c1-c1cs[c]n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.60
MEN1 O00255 3/20 0.60
MAPT P10636 3/20 0.58
NISCH Q9Y2I1 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.43
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
NQO1 P15559 1/20 0.38
CCNT1 O60563 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
CA6 P23280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17626122 0.86 ALOX5 (0.49) KMT2AMEN1MAPTALDH1A1RAB9A
SCHEMBL2752708 0.80 HSP90AA1 (0.41) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL5258364 0.78 IDO1 (0.42) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL5260087 0.78 PTPN22 (0.42) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL998182 0.76 MAPT (1.00) KMT2AMEN1MAPTNISCHSMN1; SMN2
SCHEMBL29428410 0.76 MAPT (1.00) KMT2AMEN1MAPTNISCHSMN1; SMN2
SCHEMBL12592147 0.75 MEN1 (1.00) KMT2AMEN1MAPTNISCHSMN1; SMN2
SCHEMBL14048211 0.72 MEN1 (0.69) KMT2AMEN1MAPTNISCHSMN1; SMN2
SCHEMBL1435851 0.72 CYP19A1 (0.47) MAPTSMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL22534454 0.71 MAPT (0.88) KMT2AMEN1MAPTNISCHSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1534273-A4 MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD BRISTOL MYERS SQUIBB CO (US) 2007-08-22 EP disclosed
US-6995181-B2 Modulators of the glucocorticoid receptor and method BRISTOL-MYERS SQUIBB CO. (US) 2006-02-07 US disclosed
US-20050171136-A1 Modulators of the glucocorticoid receptor and method VACCARO WAYNE (US) 2005-08-04 US disclosed
EP-1534273-A2 MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD Bristol-Myers Squibb Company (US) 2005-06-01 EP disclosed
US-20040132758-A1 Modulators of the glucocorticoid receptor and method BRISTOL-MYERS SQUIBB COMPANY 2004-07-08 US disclosed
WO-2004009017-A2 MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132758-A1 Modulators of the glucocorticoid receptor and method NR3C1, NR3C2, MC2R KMT2A 3439/4885MEN1 4737/4885MAPT 4783/4885
US-20050171136-A1 Modulators of the glucocorticoid receptor and method NR3C1, MC2R, NR3C2 KMT2A 2674/4885MEN1 4667/4885MAPT 4654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.